Jupiter Neurosciences, Inc. (JUNS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jupiter Neurosciences, Inc., a Delaware corporation and emerging growth company, on August 21, 2026. The filing discloses the entry into material definitive agreements regarding a registered direct offering and unregistered sales of equity securities under an existing Standby Equity Purchase Agreement (SEPA).
Key Financial Metrics and Capital Activities
- Registered Direct Offering: The Company agreed to sell 307,692 shares of Common Stock at $6.50 per share, generating aggregate gross proceeds of approximately $2.0 million.
- SEPA Transactions: Between August 14, 2026, and August 21, 2026, the Company sold 107,920 shares to Yorkville under the SEPA for aggregate gross proceeds of $851,194.
- Transaction Costs: The Company agreed to pay a placement agent fee of 7.0% of gross proceeds from the registered direct offering and reimburse legal expenses up to $75,000.
- Liquidity and Debt: The filing does not provide specific data on total cash balances, debt levels, or operating cash flows.
Material Changes and Agreements
The primary material change is the execution of a Securities Purchase Agreement for the registered direct offering, expected to close on or about August 24, 2026. This transaction includes a 30-day lock-up period restricting the issuance of Common Stock or Common Stock Equivalents. Additionally, the Company utilized its SEPA with Yorkville to raise additional capital at a price of 97% of the lowest daily VWAP during the applicable pricing periods.
Outlook, Risks, and Management Commentary
The Company issued a pricing press release on August 21, 2026, announcing the terms of the offering. The filing notes that the offering is subject to customary closing conditions. No specific forward-looking guidance regarding revenue, clinical milestones, or future financial performance is provided in this text. The filing includes standard risk disclosures regarding the legality of the securities issuance and the reliance on exemptions from registration for the SEPA transactions.
Key Facts for Investor Verification
- Verify the closing date of the registered direct offering (expected August 24, 2026) and the final net proceeds after deducting the 7.0% placement fee and legal expenses.
- Confirm the total number of shares outstanding post-closing to assess potential dilution from the 307,692 new shares and the 107,920 SEPA shares.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and the 30-day issuance restrictions.
- Check the Company's most recent 10-Q or 10-K for current cash runway, as this 8-K does not disclose total liquidity or burn rate.